Dr. Friese is being honored for his pioneering work discovering how inflammation is associated with nerve cell death in multiple sclerosis.

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

The FDA approved Scinopharm's generic glatiramer acetate injection for MS. This generic version of Copaxone treats relapsing forms of the disease. It reduces relapses and lesions, and may delay ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns—including a ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Join us Jan. 14 for a virtual discussion about our Rx ...

Aaron Navarro is a CBS News digital reporter. He covered the 2024 elections and was previously an associate producer for the CBS News political unit in the 2021 and 2022 election cycles. Washington — ...

Sanofi said a U.S. regulatory decision on its tolebrutinib experimental treatment for a type of multiple sclerosis would be delayed again, and that a late-stage trial for a different form of the ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another. Sanofi reported a ...